GSK and Merck drugs "meet an un-need" in prostate cancer risk reduction, says FDA panel
This article was originally published in Scrip
Executive Summary
The future of the 5 alpha reductase inhibitors (5ARIs) as approved therapies in the US for reducing the risk of prostate cancer in men at increased risk for the disease appears dimmer after a 1 December meeting of the oncologic drugs advisory (ODAC) committee of the FDA.